first approval for roche’s zalcitabine
TRANSCRIPT
MARKET NEWS
First approval for Roche's zalcitabine Roche's anti-HIV drug, zalcitabine ('Hivid'),
was approved in its first market, Austria, early in April. Zalcitabine has previously been known as dideoxycytidine or ddC.
The approval is for use in combination with zidovudine in patients with advanced HIV disease, and in patients with AIDS who are intolerant of, or unresponsive to, zidovudine treatment. According to Roche, the combination of zalcitabine and zidovudine produces better clinical responses than the use of either agent alone.
Approval for zalcitabine has been sought in a number of countries, and additional approvals are expected soon.
1523
ISSN 0156-2703/92/0502-0027/$1.00/0 C Adis ' ... national lid
27